UBS Group’s Orphazyme A/S ORPH Stock Holding History

UBS Group’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-70,000	Closed	-$169K	–	11486
2021 Q4	$169K	Buy	70,000 +67,235	+2,432%	+$237K	﹤0.01%	5843
2021 Q3	$11K	Buy	+2,765	New	+$14.2K	﹤0.01%	7961
2021 Q2	–	Sell	-311	Closed	-$3K	–	10194
2021 Q1	$3K	Sell	311 -2,016	-87%	-$24.8K	﹤0.01%	8573
2020 Q4	$25K	Buy	+2,327	New	+$23.7K	﹤0.01%	6793

Other funds holding ORPH

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

UBS Group's ORPH Position: Q1 2022 in Review

UBS Group sold out of Orphazyme A/S (ORPH) in Q1 2022, closing a stake of 70,000 shares — an estimated $169K sold.

UBS Group first reported a position in ORPH in Q4 2020 and held it in 4 quarters. The position peaked at $169K in Q4 2021. 4 funds tracked by Wall St. Rank hold ORPH as of Q1 2022.

UBS Group reported no remaining Orphazyme A/S position as of Q1 2022 after selling out during the quarter.
UBS Group sold 70,000 Orphazyme A/S shares in Q1 2022, an estimated $169K.
UBS Group first reported a position in Orphazyme A/S in Q4 2020 and held it in 4 quarters.
UBS Group's Orphazyme A/S position peaked at $169K in Q4 2021.
4 funds tracked by Wall St. Rank held Orphazyme A/S as of Q1 2022.

Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.